Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | MARK3 | P27448 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | BLK | P51451 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.44 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795054 | 0.81 | BCL6 (0.55) | BCL6AURKAMAPTCDK2PIM1 | |
| SCHEMBL824411 | 0.78 | BCL6 (0.74) | BCL6AURKAMAPTCDK2PIM1 | |
| SCHEMBL795053 | 0.77 | GAA (0.47) | BCL6MAPTRAB9AMAPK1NPC1 | |
| SCHEMBL5137042 | 0.74 | BCL6 (0.62) | BCL6AURKAMAPTCDK2PIM1 | |
| SCHEMBL8908340 | 0.74 | GAA (0.71) | BCL6AURKAMAPTCDK2PIM1 | |
| Amanozine SCHEMBL689928 | 0.74 | BCL6 (1.00) | BCL6AURKAMAPTCDK2PIM1 | |
| Amanozine SCHEMBL30264199 | 0.74 | BCL6 (1.00) | BCL6AURKAMAPTCDK2PIM1 | |
| Amanozine SCHEMBL2490900 | 0.73 | BCL6 (0.96) | BCL6AURKAMAPTCDK2PIM1 | |
| SCHEMBL14972606 | 0.73 | BCL6 (0.71) | BCL6AURKAMAPTCDK2PIM1 | |
| SCHEMBL21496120 | 0.72 | BCL6 (0.65) | BCL6MAPTCDK2PIM1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7887845-B2 | Particle of a solid dispersion composed of a water soluble polymer and etravirine or salt thereof; etravirine FDA Orange book listed patent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2010-07-08 | — | — | US | disclosed |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2007-08-23 | — | — | US | disclosed |
| US-7241458-B1 | Antiviral compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-20060127487-A1 | Antiviral compositions | VERRECK GEERT | 2006-06-15 | — | — | US | disclosed |
| EP-1225874-B1 | ANTIVIRAL SOLID DISPERSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | BCL6 3371/4885AURKA 1920/4885MAPT 879/4885 |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | BCL6 3371/4885AURKA 1920/4885MAPT 879/4885 |
| US-20060127487-A1 | Antiviral compositions | EIF2AK2, ZC3HAV1, RPL35 | BCL6 3371/4885AURKA 1920/4885MAPT 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.